1.
Lebwohl M, Lacour J-P, Liljedahl M, Lynde C, M?rch MH, Tha?i D, Warren RB. Safety of Long-Term Proactive Management with Fixed-Dose Combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam in Patients with Psoriasis Vulgaris: Results of a Phase III, Multicentre, Randomized, 52-Week, Vehicle-Controlled Trial. J of Skin [Internet]. 2020Sep.2 [cited 2024Jun.15];4(5):s31. Available from: https://www.jofskin.org/index.php/skin/article/view/980